Doc Trials LLC

1. Allergan Inc. $2,158,742 392 payments
2. AbbVie, Inc. $681,784 92 payments
3. Lexicon Pharmaceuticals, Inc. $97,425 21 payments

1. Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia $1,080,131 52 payments
2. Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $597,701 67 payments
3. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $370,092 105 payments
4. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $203,161 58 payments
5. A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment $146,156 26 payments
6. The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension $126,064 48 payments
7. A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment $95,779 23 payments
8. Lx9211.1-204-Dpn $90,968 11 payments
9. A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $83,067 60 payments
10. Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $30,063 10 payments

1. Patient care $12,778 9 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.